These data, together with our TCGA Oncomine data, support the concept that therapies targeting WT1, such as miR-642a-5p replacement treatment or 17-AAG, could reduce PCa growth and potentially represent treatment alternatives. This evidence concerns the gene WT1 and posterior cortical atrophy.